RightFit
RecruitingNot applicable

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Pilot Study for Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 79 Years
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether a heart scan plan based on each woman's risk can safely reduce scans that are not needed while still finding heart damage from treatment early. It is for women with early-stage, HER2-positive breast cancer who will receive treatment that targets HER2, a protein that helps cancer grow.

The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Women ages 18 to 79.
  • HER2-positive breast cancer confirmed by a tissue test, with about 12 months of HER2-targeted treatment planned after surgery.
  • A starting heart ultrasound shows that the heart pumps out at least 55% of the blood in its main pumping chamber with each beat.
  • Able to understand the study and agree to take part.

Who can't join

  • Past heart failure, heart attack, or heart muscle disease.
  • Atrial fibrillation, a type of irregular heartbeat, or serious heart valve disease.
  • A total past dose of anthracycline chemotherapy of 250 mg/m² or more, measured based on body size.
  • Pregnant or breastfeeding.
  • Unable to follow the study steps.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Female sex, age 18-79 years. * Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT * Baseline LVEF ≥ 55 % by 2-D echocardiography. * Ability to provide informed consent. Exclusion Criteria: * Prior HF, myocardial infarction, or cardiomyopathy. * Atrial fibrillation or significant valvular heart disease. * Cumulative anthracycline dose ≥ 250 mg/m². * Pregnancy or lactation. * Inability to comply with study procedures.

Study sites (1)

NY